VivaCT 40 Scanner

描述（由申请人提供）：我们正在申请SCANCO Medical（Viva-CT 40）的体内微型计算机断层扫描（<CT）系统的资金，该系统将位于哈佛公共卫生学院（HSPH）的屏障动物设施中，供HSPH和波士顿哈佛牙科医学院（HSDM）的生物医学研究团体使用。该系统由Viva-CT 40扫描仪、两台用于数据采集和分析的计算机以及基于异氟烷的麻醉系统组成。In Vivo <CT将主要用于在骨丢失和骨增加以及关节炎的已建立和发育模型中评价基因工程小鼠。骨和关节是显著的生物材料，其建模和重塑以生长、保持结构完整性并适应应力。这一动态过程由骨形成成骨细胞、骨吸收破骨细胞和软骨基质分泌软骨细胞控制。骨骼和关节内分解代谢和合成代谢活动之间的不平衡导致一些最常见的公共卫生问题，包括骨质疏松症，关节炎和癌症。通过对这些人类条件的基因工程小鼠模型的分析，已经了解了很多关于骨重建的分子控制。重要的是，人类和啮齿动物共享控制成骨细胞、破骨细胞和软骨细胞行为的大部分途径。体内CT机的相对较新的可用性使得对骨骼系统感兴趣的生物学家能够随着时间的推移跟踪同一小鼠的骨骼参数。这项技术可以大大提高目前资助的研究的质量，这些研究来自本提案中包括的主要（Glimcher，Olsen和Baron）和次要（Hotamisligil，Aliprantis，Jones，Lankse和Li）用户，他们每个人都使用小鼠遗传学来探测骨骼系统。Viva CT 40将被纳入HSDM现有的<CT设施，我们现在定期进行Ex Vivo <CT。HSPH管理部门的坚定承诺通过确保仪器的长期服务合同以及技术援助支持来完成这一应用。总之，Viva CT 40将使我们能够纵向比较同一小鼠随时间推移的骨参数，从而大大减少临床前研究稳健验证所需的动物数量，并促进我们PHS资助项目的及时完成。 公共卫生相关性：HSPH和HSDM的10名教职员工都使用小鼠遗传学来探测骨骼系统，他们正在向SCANCO Medical（Viva-CT 40）申请体内CAT扫描系统的资金。该仪器允许在骨丢失和随时间增长的模型中评估个体基因工程小鼠，并将为人类骨骼疾病（如骨质疏松症和关节炎）的临床前模型提供可靠的验证。

DESCRIPTION (provided by applicant): We are requesting funding for an In Vivo micro-computerized tomography (<CT) system from SCANCO Medical (Viva-CT 40) to be sited in the barrier animal facility at the Harvard School of Public Health (HSPH) for use by the biomedical research community at HSPH and the Harvard School of Dental Medicine (HSDM) in Boston. This system consists of the Viva-CT 40 scanner, two computers for data acquisition and analysis, and an isoflurane based anesthesia system. The In Vivo <CT will be primarily used to evaluate genetically engineered mice in established and developmental models of bone loss and accrual as well as arthritis. Bone and joints are remarkable biomaterials that model and remodel to grow, preserve structural integrity and adapt to stress. This dynamic process is controlled by bone forming osteoblasts, bone resorbing osteoclasts and cartilage matrix secreting chondrocytes. An imbalance between catabolic and anabolic activity within bone and joints contributes to some of the most common public health problems including osteoporosis, arthritis and cancer. Much has been learned about the molecular control of bone remodeling by the analysis of genetically engineered mouse models of these human conditions. Importantly, humans and rodents share the majority of pathways that control osteoblast, osteoclast and chondrocyte behavior. The relatively recent availability of In Vivo <CT machines has made it possible for biologists interested in the skeletal system to follow skeletal parameters in the same mouse over time. This technique could vastly improve the quality of the currently funded studies from the major (Glimcher, Olsen and Baron) and minor (Hotamisligil, Aliprantis, Jones, Lankse, and Li) users included in this proposal who each use mouse genetics to probe the skeletal system. The Viva CT 40 will be incorporated into the existing <CT facility at HSDM where we now routinely perform Ex Vivo <CT. A strong commitment from the administration at HSPH completes this application by assuring a long- term service contract for the instrument as well as support for technical assistance. In summary, the Viva CT 40 will allow us to longitudinally compare bone parameters in the same mouse over time thereby substantially reducing the number of animals needed for robust validation of preclinical studies and facilitating the timely completion of our PHS funded projects. Public Health Relevance: Ten faculty members at HSPH and HSDM who each use mouse genetics to probe the skeletal system are requesting funding for an In Vivo CAT scan system from SCANCO Medical (Viva-CT 40). This instrument allows the evaluation of individual genetically engineered mice in models of bone loss and accrual over time and will provide robust validation of preclinical models of human skeletal diseases such as osteoporosis and arthritis.